Beyond Air, Inc. entered into a securities purchase agreement on July 29, 2026, for a private placement expected to yield approximately $10.2 million in gross proceeds at closing. The company issued 167,011 shares of common stock and pre-funded warrants for up to 1,638,835 additional shares, each accompanied by Series A and Series B warrants exercisable at $5.51 per share. Institutional investors paid $5.66 per unit, while directors and executive officers including CEO Robert Goodman and CFO Daniel Moorhead paid $5.76 per unit. Total potential proceeds reach up to $30.1 million if all warrants are exercised for cash. The closing is expected on July 31, 2026, with net proceeds designated for working capital and general corporate purposes. Beyond Air operates in the medical device and biopharmaceutical industry, focusing on nitric oxide therapies for respiratory conditions.
